| HOME >> BIOLOGY >> TECHNOLOGY |
the sale of the Company's endovascular business during the fourth
quarter of fiscal year 2008.
Note: To supplement our consolidated financial statements presented in
accordance with GAAP, Kensey Nash Corporation uses non-GAAP measures
of adjusted earnings per share, which are adjusted from our GAAP
results to exclude certain expenses. These non-GAAP adjustments are
provided to enhance the user's overall understanding of our
historical and current financial performance and our prospects for
the future. We believe the non-GAAP results provide useful
information to both management and investors by excluding certain
expenses that we believe are not indicative of our core operating
results.
These non-GAAP measures will provide investors and management with
an alternative method for assessing Kensey Nash's operating results
in a manner consistent with future presentation. Further, these
non-GAAP results are one of the primary indicators management uses
for planning and forecasting in future periods. The presentation of
this additional information should not be considered in isolation or
as a substitute for results prepared in accordance with accounting
principles generally accepted in the United States.
Supplemental Non-GAAP Financial Measures and Reconciliations
Kensey Nash Corporation
Non-GAAP Financial Measures and Reconciliations
Adjusted Income and Earnings Per Share Reconciliation
(Unaudited) (Unaudited)
As Reported Non-GAAP Adjustments As Adjusted
Three Emboli
'/>"/>
| SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved |